• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Syngene

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Adare Pharma Solutions

    Quotient Sciences

    Syngene

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Allergan, Editas Announce Exercise of Development Options

    Allergan has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10

    Related CONTENT
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Vetio Animal Health
    • Top 25 Pharma and Biopharma Companies
    • Top 25 Pharma and Biopharma Companies
    • Top 25 Pharma and Biopharma Companies
    08.07.18
    Allergan and Editas Medicine announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. 

    Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States. Under the terms of the option agreement signed in March 2017, Allergan has paid Editas Medicine a fee of $15 million in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25 million from Allergan upon acceptance of an investigational new drug (IND) application for EDIT-101 by the Food & Drug Administration. 

    "CRISPR-based medicines have the potential to be game-changers for patients with both genetically-defined and genetically-treatable diseases of the eye," said David Nicholson, Ph.D., chief research and development officer, Allergan. "The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients."
     
    "Today marks a significant milestone in our collaboration with Allergan and in our work to develop genomic medicines to treat eye diseases," said Katrine Bosley, president and chief executive officer, Editas Medicine. "Allergan is a long-time innovator in ophthalmology, and their deep experience in developing, manufacturing, and commercializing medicines globally will meaningfully advance the EDIT-101 program and maximize our ability to bring this transformative medicine to people living with LCA10."

    In March 2017, the two companies entered a strategic alliance and option agreement under which Allergan received exclusive access and the option to license up to five of Editas Medicine's genome editing programs for ocular diseases, including EDIT-101. Under the terms of the agreement, Allergan is responsible for development and commercialization of optioned products, subject to Editas Medicine's option to co-develop and share equally in the profits and losses of two optioned products in the United States. Editas Medicine is also eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis where the parties are not sharing profits and losses. 
    Related Searches
    • patients
    • Development
    • chief executive officer
    • license
    Suggested For You
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Vetio Animal Health Vetio Animal Health
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    06	NOVARTIS 06 NOVARTIS
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    18	ALLERGAN 18 ALLERGAN
    13	Teva 13 Teva
    11	Amgen 11 Amgen
    Ajinomoto Althea Makes Key VP Hires Ajinomoto Althea Makes Key VP Hires
    Millicent Pharma Launches Operations Millicent Pharma Launches Operations
    Allergan to Acquire Aptinyx Compound  Allergan to Acquire Aptinyx Compound
    BMS and Flatiron Health Expand Collaboration BMS and Flatiron Health Expand Collaboration
    PITT, Thermo Fisher Form Pharmacogenomics Center of Excellence PITT, Thermo Fisher Form Pharmacogenomics Center of Excellence

    Related Breaking News

    • Breaking News | Drug Development | Industry News
      Bristol Myers Squibb Expands at Cambridge Crossing

      Bristol Myers Squibb Expands at Cambridge Crossing

      Adds remaining 113,000 square feet to its initial lease at 250 Water Street.
      Kristin Brooks 04.16.21

    • Breaking News | Drug Development | Industry News
       Amgen Completes Five Prime Acquisition

      Amgen Completes Five Prime Acquisition

      Gains pipeline of immuno-oncology and targeted cancer therapies, including a Phase 3 trial-ready, first-in-class program for gastric cancer.
      Kristin Brooks 04.16.21

    • Breaking News | Drug Development | Industry News
      BioVersys Gets EIB Funds to Address Antimicrobial Resistance

      BioVersys Gets EIB Funds to Address Antimicrobial Resistance

      Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumannii
      Kristin Brooks 04.14.21


    • Breaking News | Clinical Trials | Drug Development | Trials & Filings
      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      FDA Accepts Airway Therapeutics’ IND for COVID Treatment

      To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
      Kristin Brooks 04.12.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Sanofi Acquires Tidal Therapeutics

      Sanofi Acquires Tidal Therapeutics

      Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.
      Kristin Brooks 04.12.21

    • Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
      Ascendia Pharmaceuticals Poised for Expansion

      Ascendia Pharmaceuticals Poised for Expansion

      CDMO secures growth equity investment from Signet Healthcare Partners.
      Tim Wright, Editor, Contract Pharma 04.09.21


    • Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News
      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate

      Work together to develop and commercialize CHI’s novel dry-powder inhaler product.
      Charles Sternberg, Assistant Editor 04.07.21

    • Breaking News | Clinical Trials | Drug Development | Industry News
      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

      To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.
      Kristin Brooks 04.06.21

    • Breaking News | Clinical Trials | CRO News | Drug Development
      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      Moleculin Selects IQVIA Biotech to Advance COVID Treatment

      IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
      Kristin Brooks 04.06.21


    • Breaking News | Drug Development
      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio

      Expands its oncology leadership capabilities in the U.S.
      Charles Sternberg, Assistant Editor 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.
      Kristin Brooks 04.01.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.
      Kristin Brooks 03.30.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
      Chime Biologics Expands CDMO Capabilities

      Chime Biologics Expands CDMO Capabilities

      Completes $190 million financing round to accelerate capacity expansion.
      Tim Wright, Editor, Contract Pharma 03.29.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CyanVac and Exothera Enter COVID-19 Vaccine Partnership

      CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.
      Tim Wright, Editor, Contract Pharma 03.25.21

    • Breaking News | Drug Development | Facilities | Industry News | Parenterals
      Eisai Begins Construction of New Injection/Research Building

      Eisai Begins Construction of New Injection/Research Building

      To accommodate expanded drug discovery targets and new modalities such as antibodies, ADCs, and nucleic acid drugs.
      Kristin Brooks 03.22.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login